Google
MLTX 株価分析 — MOONLAKE IMMUNOTHERAPEUTICS (Healthcare >> Biotechnology)
MLTX に関するよくある質問
MLTXのROE（自己資本利益率）は？
MOONLAKE IMMUNOTHERAPEUTICSのROEは-101.20%です。
MLTXの配当利回りは？
MOONLAKE IMMUNOTHERAPEUTICSの配当利回りは0.00%です。
MLTXの品質スコア（Quality Score）は？
当社のAIはMLTXの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
MLTXは今が買い時ですか？
当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
MLTXはどのセクターに属しますか？
MOONLAKE IMMUNOTHERAPEUTICSはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
MLTX AI Analysis Summary
Our AI summary for MLTX: MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -101.20%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 18.44
Price
-0.55
(-2.90%)
Day Change
|
|
|---|
MLTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 18.44 |
| PBV / Sector |
6.36 / 5.20
|
| Earning Per Share | -2.93 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
20.21 M
GREAT
|
| Average 1W Daily Value |
15.22 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:10 |
| Symbol | MLTX |
| Name | MOONLAKE IMMUNOTHERAPEUTICS |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 85.06 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,615.32 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Dorfstrasse 29, Zug, Switzerland, 6300
Phone: 41 415108022
Website: https://www.moonlaketx.com
Employees: 130
Sector: Healthcare >> Biotechnology
Description: MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
